{
  "id": "5e29fe76aa19d74431000007",
  "type": "yesno",
  "question": "Has LB-100 been tested in clinical trials?",
  "ideal_answer": "Yes, a phase I trial has been performed to assess the safety, tolerability, and potential activity of LB-100, a first-in-class small-molecule inhibitor of protein phosphatase 2A (PP2A) in adult patients with progressive solid tumors.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28039265"
  ],
  "snippets": [
    {
      "text": "To determine the MTD and to assess the safety, tolerability, and potential activity of LB-100, a first-in-class small-molecule inhibitor of protein phosphatase 2A (PP2A) in adult patients with progressive solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28039265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28039265",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}